Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 3 (2), 101-7

Effect of Probiotics on Symptoms in Korean Adults With Irritable Bowel Syndrome

Affiliations

Effect of Probiotics on Symptoms in Korean Adults With Irritable Bowel Syndrome

Kyoung Sup Hong et al. Gut Liver.

Abstract

Background/aims: Irritable bowel syndrome (IBS) is a troublesome disease. Some strains of probiotics reportedly exert remarkable immunomodulatory effects, and so we designed a prospective double-blind randomized placebo-controlled clinical study to assess their effects in Korean adults with IBS.

Methods: IBS patients who met Rome III criteria were randomly assigned to receive composite probiotics or placebo. A total of 20 billion lyophilized bacteria were administered twice daily for 8 weeks. Primary outcome variables were symptom scores consisting of abdominal pain, flatulence, defecation discomfort, and sum of symptom scores. A visual analogue scale was used to quantify the severity. Secondary outcome variables consisted of the quality of life and bowel habits including defecation frequency and stool form.

Results: Thirty-six and 34 patients were randomized to the probiotics and placebo groups, respectively. Intention-to-treat analysis showed significant reductions in pain after 8 weeks of treatment: -31.9 and -17.7 in the probiotics and placebo groups, respectively (p=0.045). The reductions in abdominal pain, defecation discomfort, and sum of scores were more significant in 58 patients with a score of at least 3 on the baseline stool-form scale.

Conclusions: Composite probiotics containing Bifidobacterium bifidum BGN4, Lactobacillus acidophilus AD031, and other species are safe and effective, especially in patients who excrete normal or loose stools.

Keywords: Bifidobacterium bifidum; Irritable bowel syndrome; Probiotics.

Figures

Fig. 1
Fig. 1
Pain and flatulence scores analyzed over 4- and 8-week treatment periods.
Fig. 2
Fig. 2
Defecation discomfort and sum of scores analyzed over 4- and 8-week treatment periods.

Similar articles

See all similar articles

Cited by 21 articles

See all "Cited by" articles

References

    1. Everhart JE, Renault PF. Irritable bowel syndrome in office-based practice in the United States. Gastroenterology. 1991;100:998–1005. - PubMed
    1. Talley NJ, Zinsmeister AR, Van Dyke C, Melton LJ., 3rd Epidemiology of colonic symptoms and the irritable bowel syndrome. Gastroenterology. 1991;101:927–934. - PubMed
    1. Park KS, Ahn SH, Hwang JS, et al. A survey about irritable bowel syndrome in South Korea: prevalence and observable organic abnormalities in IBS patients. Dig Dis Sci. 2008;53:704–711. - PubMed
    1. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology. 2002;122:1778–1783. - PubMed
    1. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology. 2007;132:913–920. - PubMed
Feedback